MedTrace Logo

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

NCT01452607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-06-29

No results posted yet for this study

Summary

A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.

Conditions

Interventions

DRUG

SPI-1005

200 mg Ebselen oral capsules (SPI-1005), single dose

DRUG

Placebo

0 mg Ebselen oral capsules (SPI-1000), single dose

Sponsors & Collaborators

  • Sound Pharmaceuticals, Incorporated

    lead INDUSTRY

Principal Investigators

  • James C. Kisicki, M.D. · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01452607 on ClinicalTrials.gov